111 results about "Hiv disease" patented technology

A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

The invention discloses a five-membered sulfur-containing heterocyclic nucleoside derivative and application thereof in an anti-human immunodeficiency virus (HIV) active medicine, and belongs to the technical field of medicinal chemistry. A series of five-membered sulfur-containing heterocyclic ring nucleoside compounds are synthesized through a Sulfa-Michael / Aldol cascade reaction. The result shows that in an anti-HIV virus test, the five-membered sulfur-containing heterocyclic nucleoside lead compound 42a has the optimal anti-HIV-1 virus activity, and a new structural unit is provided for antiviral candidate drug molecules.

The invention discloses a medicine composition containing homoharringtonine and application of the medicine composition in preparation of an anti-HIV (human immunodeficiency virus) medicine. The medicine composition is composed of the homoharringtonine and a nucleoside reverse transcriptase inhibitor or a non-nucleoside reverse transcriptase inhibitor, the nucleoside reverse transcriptase inhibitor is selected from one of the compounds of zidovudine, lamivudine and abacavir, and the non-nucleoside reverse transcriptase inhibitor is selected from one of the compounds of nevirapine, efavirenz and rilpivirine. The pharmaceutical composition has a remarkable synergistic effect on treatment of HIV, the curative effect of the medicine is improved, the dosage of a single medicine is reduced, the toxic and side effects are reduced, the generation of viruses can be remarkably inhibited by combined medication, a very remarkable antiviral effect is generated, and the treatment current situation of HIV-1, especially middle and advanced AIDS, is improved.

The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4′-Ethynyl-2-fluoro-2′-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and / or the treatment, prophylaxis and / or delay in the onset or progression of AIDS or ARC.

The invention discloses an AIDS molecular propagation network monitoring method and device based on deep learning classification, and the method comprises the steps: collecting AIDS virus gene sequence data and social attribute data of AIDS patients, calculating a genetic distance and a genetic distance matrix, and converting the genetic distance and the genetic distance matrix into AIDS image data; then constructing an AIDS neural network model to output propagation network characteristics, obtaining virus data classification of different AIDS virus gene sequences according to the propagation network characteristics, selecting a target classification result, obtaining a propagation path and a propagation speed, and further knowing the propagation dynamic state of the AIDS virus. Predicting the transmission risk of an HIV gene sequence corresponding to the HIV image data; according to the embodiment of the invention, the transmission of the HIV not only depends on gene sequence data, but also provides more accurate and comprehensive transmission risk collection and distribution in combination with social attributes such as social relationship and gender of the propagator, and can identify higher transmission risks, so that prevention measures can be implemented in a targeted manner.

The invention discloses a capsid inhibitor as well as a preparation method and application thereof. The capsid inhibitor can occupy a central hole of a virus capsid protein hexamer, so that nucleotide introduction is inhibited, reverse transcription in a virus capsid is effectively blocked, meanwhile, formation of capsid protein lattices is interfered, and the capsid inhibitor has excellent antiviral activity, for example, the capsid inhibitor shows remarkable anti-human immunodeficiency virus activity.

This invention provides a method for synthesizing the anti-AIDS drug enovirine. This invention belongs to the field of pharmaceutical preparation technology. The synthesis method includes the following steps: (1) SM1 compound reacts with Grignard reagent and then reacts with SM2 compound to obtain compound III; (2) Compound III undergoes oxidation reaction to obtain compound II; (3) Compound II undergoes demethylation reaction under the action of demethylation reagent to obtain compound I; (4) Compound I undergoes ethylation reaction to obtain enovirine. The synthesis route of this invention effectively avoids the use of highly toxic cyanide reagents and expensive heavy metal catalysts. At the same time, the reaction conditions of this route are simple and mild, with high yield, and have excellent industrialization prospects.

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The application discloses a kind of diaromatic pyrimidine compounds containing fused heterocycle and preparation method and application thereof.The compound has the structure shown in general formula I.The application further relates to pharmaceutical compositions containing the compound of formula I.Active screening experiments show that the compound of the application has good anti-HIV and CHIKV activity, and therefore the application further provides the use of the above-mentioned compound in the preparation of anti-AIDS drugs and anti-Chikungunya virus drugs.

The invention discloses application of a gp130 inhibitor in preparation of a medicine for treating virus infection, and relates to the technical field of medicines. Experiments prove that combination of IL-6 family cell factors and a gp130 receptor is inhibited, so that downward signal transmission of a JAK2 / STAT3 signal channel triggered by the IL-6 family cell factors is inhibited, the purposes of inhibiting cell fusion induced by SARS-CoV-2 spike protein and further influencing replication and propagation of SARS-CoV-2 are achieved, and a small-molecule inhibitor SC144 is an inhibitor of gp130, has a remarkable effect of inhibiting SARS-CoV-2 virus replication and has a good application prospect. Meanwhile, the traditional Chinese medicine composition also has a remarkable effect of inhibiting replication of viruses such as human immunodeficiency virus, herpes simplex virus and respiratory syncytial virus.

A compound of formula I or a stereoisomer, isotopic isomer, tautomer or pharmaceutically acceptable salt thereof: wherein a ligand that binds to Nef protein (NB) is covalently linked to a ligand that binds to E3 ligase cerebron (CB) via a linker (L).

The invention relates to the technical field of AIDS prevention and treatment blood sampling detection, and discloses AIDS prevention and treatment blood sampling detection equipment which comprises a shell mechanism, the shell mechanism comprises a shell, a display screen, an indicator light and an operation button, the display screen is installed on the front end face of the shell, the indicator light is arranged on the right side of the display screen, and the operation button is arranged on the right side of the display screen. By means of the blood sampling mechanism, the sample transfer mechanism and the control mechanism, when blood is sampled, the microprocessor accurately controls the puncturing depth and the blood sampling speed of the microneedle array according to feedback signals of the pressure sensor, and the blood sampling speed of the microneedle array can be accurately controlled according to the feedback signals of the pressure sensor. According to the device, the safety, stability and high efficiency of the blood sampling process are ensured, during detection, all parts of the device operate efficiently and stably under the coordination control of the control mechanism, automatic and intelligent operation from blood sampling to detection analysis is achieved, and the blood detection efficiency and accuracy in AIDS prevention and treatment work are improved.

The invention discloses an AIDS (acquired immune deficiency syndrome) short-term amplification prediction and early warning method and device, electronic equipment and a medium, which are used for solving the problem of how to effectively predict the short-term growth trend of AIDS cases in a region and give an early warning in time under the conditions of short data time span and sparse data. Acquiring newly added data and public attention data of the AIDS cases in the preset time window up to the month in the to-be-detected area; wherein the to-be-detected area comprises a plurality of sub-areas; inputting the newly added data of the AIDS cases and the public attention data into a short-term amplification prediction model for binary pre-training based on a unified large model framework and joint parameter fine tuning, and outputting prediction probabilities of reaching the preset AIDS case amplification in the next month of each sub-region through binary prediction; and for each sub-region, when the prediction probability indicates that the number of newly added AIDS cases in the next month of the sub-region meets a preset AIDS case amplification early warning condition, generating an early warning suggestion of the sub-region.

The invention belongs to the technical field of biological medicine, and particularly discloses application of quercetin in improvement of intestinal barrier injury. According to the application disclosed by the invention, the flavonoid quercetin is found to be possibly a potential medicine for improving the intestinal barrier injury of an HIV infected person for the first time, and the flavonoid quercetin has important clinical significance in finding an effective way for improving the intestinal barrier injury of the HIV infected person and reducing the disease risk of non-AIDS related complications in the population. According to the invention, the in-vitro established Caco-2 intestinal barrier model destroyed by the HIVgp120 protein is used for screening the flavonoid compound with a repairing effect for the first time, and the flavonoid compound quercetin is used for exploring whether the flavonoid compound quercetin can improve the intestinal barrier injury destroyed by the HIVgp120 protein or not.

The invention relates to the technical field of biological medicines, in particular to an injection for treating AIDS and a preparation method thereof. The extraction method of the sulfate algae polysaccharide comprises the following steps: mixing seaweed meal, cellulase and water, carrying out enzymolysis, and extracting for 10-12 hours to obtain an extract; filtering, adding magnesium chloride hexahydrate into filtrate, standing for 20-30 minutes, centrifuging, taking supernatant, removing impurities, adding absolute ethyl alcohol until the final concentration is 55-65%, and precipitating polysaccharide; and purifying the precipitated crude polysaccharide, and freeze-drying to obtain the sulfate algae polysaccharide. The purity of the sulfate algae polysaccharide is greater than or equal to 95%, and the sulfate algae polysaccharide is cooperated with lentinan to obtain a safe and stable injection with an excellent treatment effect on AIDS (Acquired Immune Deficiency Syndrome). And a new scheme is provided for treatment of AIDS.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

The present invention relates to the technical field of drug for treatment of AIDS. Disclosed are a polycyclic carbamoyl pyridone derivative, a preparation method therefor, and pharmaceutical composition thereof. The derivative comprises the compound represented by formula (I)-1 or formula (I)-2, or an isomer, pharmaceutically acceptable salt, hydrate or solvate thereof. At least one group of functional groups in (1)-(3) below and a ring A form a spirolcycle or spiroheterocycle: (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; the polycyclic carbamoyl pyridone derivative can selectively inhibit the activity of HIV integrase, and thus can be used for preventing and treating AIDS.

A production device, method and application of nano-sized zinc molybdate. The device includes a double-cone mixer; an elevator is obliquely provided at a bottom of a discharge port of the double-cone mixer; a rear end of the elevator is located above a feeder; the feeder is connected to one end of an electric heating converter, an other end of the electric heating converter is connected to a finished product bin; a top of the finished product bin is provided with an atomizing nozzle for adding nanomaterial dispersant; the atomizing nozzle is connected to a syringe pump by pipeline. High-purity nano-sized molybdenum trioxide and nano-sized zinc oxide are adopted to synthesize nano-sized zinc molybdate in an electric heating converter. The nano-sized zinc molybdate prepared by the device and method can be used for treatment of African swine fever virus, coronavirus, and AIDS phase I, Ebola, dengue fever, polio viruses.

The invention discloses an AIDS infection course prediction model and an establishment method thereof, and relates to the technical field of AIDS diagnosis, the prediction model comprises an AIDS combined fungal infection prediction model and an AIDS combined multi-infection prediction model; the formula of the AIDS combined fungal infection prediction model is as follows: logistic (p) =-5.838 to 0.348 * CD4 + T + 0.128 * CD8 + T + 7.329 * CD4 / CD8 + 8.236 * CD64; the formula of the AIDS combined fungal infection prediction model is as follows: logistic (p) =-0.824 to 0.182 * CD4 + T + 0.054 * CD8 + T-0. 065 * L / CD45. The established prediction model for the disease progress of the AIDS patient is helpful for further improving the definite diagnosis rate of the AIDS combined fungal infection patient and the AIDS combined multi-infection patient so as to promote the early treatment of the AIDS combined fungal infection patient and the AIDS combined multi-infection patient; meanwhile, the casualty rate of the AIDS patient caused by complications such as opportunity infection is reduced as much as possible, and a theoretical basis and a reference basis are provided for early diagnosis and precise treatment of the AIDS patient clinically.

The invention discloses an application of a PHD3 inhibitor in prevention and treatment of AIDS (acquired immune deficiency syndrome). Through multidisciplinary research means of immunology, biochemistry and the like, the situation that virus antisense protein ASP inhibits generation of I-type IFN in the HIV-1 infection process is analyzed, immune escape is achieved, and a latent infection mechanism is established. In the aspect of mechanism, the ASP can play the inhibiting role after transcriptional expression into protein in a body cell through post-translational modification, the 47-site proline of the ASP can be helped to realize the capability of inhibiting the immune response of the body after hydroxylation modification, and the post-translational modification is realized by depending on proline hydroxylase 3 (PHD3) of a host. On the basis of mechanism research, it is found that a PHD3 inhibitor Molidustat counteracts hydroxylation of PHD3 to ASP, so that immune escape of HIV-1 is blocked, infection is antagonized, and good development prospects of AIDS treatment and prevention drugs are shown.

The invention relates to the technical field of disease infection early warning, and discloses a male and male behavior AIDS infection internet self-assessment intervention system, which comprises a feature sequence generation module, which is used for collecting feature data of known AIDS virus infected persons and contact persons thereof to generate feature sequences; the social network graph construction module is used for constructing a social network graph; the social network graph splitting module is used for dividing the social network graph into a plurality of sub-graphs through a community detection algorithm based on modularity optimization; the risk level early warning module is used for inputting each sub-graph into an AIDS early warning model and outputting the risk level of a known AIDS virus infected person or a person in contact with the known AIDS virus infected person; the early warning measure generation module is used for generating early warning measures according to the risk levels; according to the AIDS early warning method, the social network graph is subjected to space-time analysis through the AIDS early warning model, the risk level of each person in the social network graph is automatically predicted, and the early warning measures are accurately generated according to the risk levels, so that the AIDS early warning efficiency is improved.

The invention discloses an efficient production process of an umbilical cord mesenchymal stem cell preparation in the field of stem cells, which comprises the following steps: S101, collection and separation of umbilical cord mesenchymal stem cells: under a sterile condition, separating Walton's jelly by adopting a tissue block culture method, taking out an umbilical cord from an umbilical cord bottle, transferring the umbilical cord into a sterile culture dish, and reserving a sample of a protective solution in the umbilical cord bottle for sterile detection; washing the umbilical cord with normal saline, cutting off two ends of the umbilical cord, discarding the umbilical cord, segmenting the umbilical cord for about 3-4cm, washing to remove blood, umbilical cord veins, two arteries and amniotic membranes, collecting the Walton's jelly, and transferring the Walton's jelly into a 50ml centrifugal tube; adding a small amount of the culture medium, cutting the Walton's gum into pieces with a size of about 1mm < 3 > by using scissors, and centrifugally washing for two times by using normal saline; the preparation produced by the invention is negative in detection of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, syphilis antibody, cytomegalovirus and mycoplasma, and is high in extraction efficiency and convenient to popularize.

The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and / or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula Ior a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.

The application discloses a kind of chronic infectious disease digital people health management system construction method, it relates to AIDS nursing management technical field.Based on Triangle model, the management classification and characteristics of HIV patients are determined by latent profile and association rule analysis, and it is embedded into applet using agile development;Based on the basic nursing framework, the commonality and difference of patients in different levels are explored Care needs;Through the preliminary construction of AIDS hierarchical case management program by range review and focus group interview, the final draft is formed by revising and improving through written evaluation and field demonstration, and the well-constructed management program is embedded into a digital human interaction platform based on artificial intelligence.The application protects the privacy of patients, alleviates the shortage of medical human resources, meets the growing health needs of HIV patients, improves patient satisfaction and improves the quality of HIV care services.

The application provides a 4-quinazolinone derivative containing a benzene sulfonamide piperazine ketone and a preparation method and application thereof. The derivative has the structure shown in the following general formula I. The application further relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / HIV-2 capsid protein regulator in preparation of an anti-AIDS drug.

The invention belongs to the technical field of medicines, and particularly relates to a dihydropteridine-6 (5H)-ketone skeleton compound as well as a preparation method and application thereof. The dihydropteridine-6 (5H)-ketone skeleton compound disclosed by the invention is an HIV-1 (Human Immunodeficiency Virus-1) non-nucleoside reverse transcriptase inhibitor; the invention also comprises pharmaceutical salts, hydrates, solvates, polycrystals or co-crystals of the compounds, precursors and derivatives with the same biological functions of the compounds, a preparation method of the compounds and application of a composition containing one or more of the compounds in preparation of related drugs for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

Provided are membrane fusion inhibitors, derivatives thereof, pharmaceutical compositions thereof, and pharmaceutical uses thereof for inhibiting HIV and drug-resistant strains thereof.

The invention discloses an application of a UFMylation regulator in preparation of a medicine for resisting HIV (Human Immunodeficiency Virus) infection. According to the application disclosed by the invention, through in-vivo and in-vitro pharmacodynamic experiments, the inhibition effect of a UFMylation regulator, namely a UFSP2 inhibitor Compond-8, on an HIV (Human Immunodeficiency Virus) is evaluated. Experimental results show that the Compound 8 can significantly inhibit the replication of MT-4 cells, primary CD4 + T cells and HIV viruses in mice, can still maintain low virus load after drug withdrawal, has no obvious influence on the proliferation of normal cells and the weight of mice, and has a good anti-HIV infection effect and high safety. The invention reveals that the Compound 8 effectively inhibits HIV-1 replication for the first time, prompts that the Compound 8 can be used as a candidate drug of an HIV-1 treatment drug, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of HIV infection resistance.